Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 8/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14581371 | 0.90 | GSK3B (0.46) | CYP19A1GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL14418865 | 0.83 | GSK3B (0.41) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL13120630 | 0.82 | CDK2 (0.59) | CYP19A1GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13289432 | 0.82 | CDK2 (0.47) | CYP19A1NAMPTGSK3BCDK2CCNA2 | |
| SCHEMBL14545978 | 0.81 | GSK3B (0.47) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL12954093 | 0.79 | CYP19A1 (0.45) | CYP19A1NAMPTGSK3BCDK2CCNA2 | |
| SCHEMBL13120677 | 0.79 | CDK2 (0.62) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL12954486 | 0.78 | BRAF (0.38) | GSK3BNPC1RAB9A | |
| SCHEMBL14607254 | 0.78 | RAF1 (0.37) | GSK3BKMT2ANPC1RAB9A | |
| SCHEMBL14301243 | 0.77 | GSK3B (0.48) | GSK3BCDK2CCNA2CCNA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | CYP19A1 931/4885NAMPT 677/4885GSK3B 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.